Literature DB >> 34059144

Enhancement and evaluation of a prescription audit system for direct oral anticoagulants using a check sheet.

Naoto Ishikawa1, Hanae Oshikiri1, Shinya Takasaki2, Masafumi Kikuchi1, Taku Obara1, Kazutoshi Akasaka1, Masaki Matsuura1, Hiroaki Yamaguchi1, Nariyasu Mano1.   

Abstract

BACKGROUND: Renal function and use of concomitant medications should be carefully monitored in patients subjected to treatment with direct oral anticoagulants (DOACs); the dose should be individually designed for each patient. Owing to the complex therapeutic indications and dose reduction criteria, pharmacists exercise caution when determining the optimal dose for each patient. A DOAC check sheet has been developed that is automatically printed in the dispensing room at the same time as the prescription and can be used by pharmacists to dispense DOACs promptly and correctly. The purpose of this study was to evaluate the system for dispensing DOACs using a check sheet.
METHODS: The study was conducted at Tohoku University Hospital in Japan; prescriptions containing DOACs dispensed by the hospital pharmacists were evaluated. The DOAC check sheet described indications, dosage regimens, dose reduction criteria, and contraindications for each drug and included the patient's information. The check sheet was set to print automatically in the dispensing room at the same time as the prescription when an inpatient was prescribed DOACs. This check sheet was evaluated using a prescription survey and a questionnaire for pharmacists.
RESULTS: The usefulness of this check sheet for the correct use of DOACs was evaluated. There were four inquiries out of 642 (0.6%) prescriptions from pharmacists to physicians regarding DOAC prescriptions, such as the dose introduced before DOAC check sheet utilization, and there were 21 out of 905 (2.3%) prescriptions when the DOAC check sheet was used it, showing a significant increase (p = 0.0089). After the introduction of this sheet, overdoses of DOACs were identified at the time of dispensing. Of the 52 pharmacists who responded to the questionnaire, 51 (98%) stated that the check sheet was useful.
CONCLUSION: The use of the DOAC check sheet is likely to render safety to DOAC drug therapy for individual patients.

Entities:  

Keywords:  Anticoagulant; Direct oral anticoagulant; Intervention; Pharmacist; Prescription

Year:  2021        PMID: 34059144     DOI: 10.1186/s40780-021-00205-y

Source DB:  PubMed          Journal:  J Pharm Health Care Sci        ISSN: 2055-0294


  6 in total

1.  Dabigatran (Pradaxa).

Authors:  J Comin; D F Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  2012-02-16       Impact factor: 3.825

Review 2.  Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.

Authors:  Paul A Reilly; Joanne van Ryn; Oliver Grottke; Stephan Glund; Joachim Stangier
Journal:  Am J Emerg Med       Date:  2016-09-28       Impact factor: 2.469

3.  Reduction in the Doses of Direct Oral Anticoagulants and Risk of Ischemic Stroke Events: A Hospital Survey.

Authors:  Aya Ueda; Shinji Toki; Chisato Kitayama; Manabu Akazawa
Journal:  Biol Pharm Bull       Date:  2020-05-12       Impact factor: 2.233

4.  Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.

Authors:  Xiaoxi Yao; Nilay D Shah; Lindsey R Sangaralingham; Bernard J Gersh; Peter A Noseworthy
Journal:  J Am Coll Cardiol       Date:  2017-06-13       Impact factor: 24.094

5.  Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.

Authors:  Megan E Barra; John Fanikos; Jean M Connors; Katelyn W Sylvester; Gregory Piazza; Samuel Z Goldhaber
Journal:  Am J Med       Date:  2016-06-21       Impact factor: 4.965

Review 6.  The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: A review of the literature.

Authors:  Jacob Weber; Ali Olyaei; Joseph Shatzel
Journal:  Eur J Haematol       Date:  2019-02-07       Impact factor: 2.997

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.